SP
GILD icon

Saranac Partners’s Gilead Sciences GILD Stock Holding History

Saranac Partners’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-3,164
Closed -$246K – 124
2026
Q1 		$246K Buy
+3,164
New +$443K 0.11% 83
2025
Q4 		– Sell
-1,060
Closed -$118K – 103
2025
Q3 		$118K Buy
+1,060
New +$120K 0.02% 237

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Saranac Partners's GILD Position: Q2 2026 in Review

Saranac Partners sold out of Gilead Sciences (GILD) in Q2 2026, closing a stake of 3,164 shares — an estimated $246K sold.

Saranac Partners first reported a position in GILD in Q3 2025 and held it in 2 quarters. The position peaked at $246K in Q1 2026. 2,291 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Saranac Partners reported no remaining Gilead Sciences position as of Q2 2026 after selling out during the quarter.
  • Saranac Partners sold 3,164 Gilead Sciences shares in Q2 2026, an estimated $246K.
  • Saranac Partners first reported a position in Gilead Sciences in Q3 2025 and held it in 2 quarters.
  • Saranac Partners's Gilead Sciences position peaked at $246K in Q1 2026.
  • 2,291 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Saranac Partners's 13F filing for Q2 2026, filed 13 Aug 2026.